Policy | May 10, 2021
DCGI approves anti-COVID drug developed by DRDO
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
